Restricted accessResearch articleFirst published online 2026-4
Evolution of the Burden of Carbapenem-Resistant Klebsiella pneumoniae Infections in the Elderly,1990–2021: Global Trends,Regional Heterogeneity,and Health Inequalities
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a critical global health threat, particularly for older adults. Understanding its precise burden and the associated health inequalities in the elderly population is crucial for informed policy-making.
Methods:
Using data from the Global Burden of Disease 2021 study, we analyzed deaths and disability-adjusted life years attributable to and associated with CRKP in individuals aged ≥ 65 years from 1990 to 2021. We calculated age-standardized rates, assessed temporal trends via average annual percentage change (AAPC), and quantified health inequalities using the Slope Index of Inequality (SII) and Relative Concentration Index. Frontier analysis identified countries with the greatest potential for burden reduction.
Results:
The CRKP burden in the elderly increased substantially over the past three decades, as the age-standardized mortality rate associated with CRKP more than doubled from 7.44 (95% CI: 5.65 to 9.23) to 16.17 (95% CI: 13.1 to 19.25) per 100,000 (AAPC = 2.54, p < 0.001), with the most rapid increases occurring in South Asia, Eastern Europe, and Latin America. Conversely, high-income regions such as Western Europe witnessed substantial declines. Health inequalities widened markedly, as the absolute mortality gap (SII) associated with CRKP expanded from −8.69 (95% CI: −11.25,−6.14) to −41.96 (95% CI: −46.97,−36.95), an approximate fivefold increase. Frontier analysis further revealed significant potentially avoidable burden in low- and middle-income countries, independent of socioeconomic development.
Conclusion:
Formal assessment of socioeconomic trends and health inequalities demonstrates an increasing concentration of the CRKP burden in low- and middle-income regions, exacerbating global health inequities. Combating this requires integrated strategies that combine antimicrobial stewardship and infection control with broader improvements in health care infrastructure and social determinants.
SatiH, CarraraE, SavoldiA, et al.; WHO Bacterial Priority Pathogens List Advisory Group. The WHO bacterial priority pathogens list 2024: A prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. Lancet Infect Dis, 2025; 25(9):1033–1043.
2.
ZhenX, Stålsby LundborgC, SunX, et al.Clinical and economic burden of carbapenem-resistant infection or colonization caused by Klebsiella pneumoniae, pseudomonas aeruginosa, Acinetobacter baumannii: A multicenter study in China. Antibiotics (Basel), 2020; 9(8):514.
3.
PulingamT, ParumasivamT, GazzaliAM, et al.Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome. Eur J Pharm Sci, 2022; 170:106103.
4.
ZhouC, SunL, LiH, et al.Risk factors and mortality of elderly patients with hospital-acquired pneumonia of Carbapenem-resistant Klebsiella pneumoniae infection. Infect Drug Resist, 2023; 16:6767–6779.
5.
CollaboratorsGAR. Global burden of bacterial antimicrobial resistance 1990-2021: A systematic analysis with forecasts to 2050. Lancet, 2024; 404(10459):1199–1226.
6.
WanX, MiaoR, ZhangN, et al.Global burden of antimicrobial resistance in lower respiratory infections in 2021: A systematic analysis. Int J Antimicrob Agents, 2025; 65(2):107431.
7.
GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: A systematic analysis for the global burden of disease study 2021. Lancet, 2024; 403(10440):2133–2161.
8.
LiX, FanH, ZiH, et al.Global and regional burden of bacterial antimicrobial resistance in urinary tract infections in 2019. J Clin Med, 2022; 11(10):2817.
9.
CollaboratorsEAR. The burden of bacterial antimicrobial resistance in the WHO European region in 2019: A cross-country systematic analysis. Lancet Public Health, 2022; 7(11):e897–e913.
10.
LinY, FuM, LinR, et al.Trends in the prevalence of steatotic liver disease among Chinese adults, 2015-2023: A nationwide cross-sectional study. Hepatol Commun, 2025; 9(9):e0785.
11.
NieZ, ZhangR, GuoY, et al.Comparison of the burden of musculoskeletal disorders between China and worldwide data using the global burden of disease dataset from 1990 to 2021. Ann Med, 2025; 57(1):2529578.
12.
HosseinpoorAR, SchlotheuberA, NambiarD, et al.Health equity assessment toolkit plus (HEAT Plus): Software for exploring and comparing health inequalities using uploaded datasets. Glob Health Action, 2018; 11(sup1):1440783.
13.
BaykedaTA, NegashWD, BelachewTB, et al.Trends of socioeconomic and geographic inequalities in severe wasting among under-five children in Ethiopia from 2000 to 2019: Using the WHO health equity assessment toolkit. Sci Rep, 2024; 14(1):948.
14.
WangX, ShangA, ChenH, et al.Global, regional, and national disease burden of multidrug-resistant tuberculosis without extensive drug resistance, 1990–2021: Findings from the global burden of disease study 2021. Drug Resist Updat, 2025; 82:101265.
15.
SaeedDK, HasanR, NaimM, et al.Readiness for antimicrobial resistance (AMR) surveillance in Pakistan; a model for laboratory strengthening. Antimicrob Resist Infect Control, 2017; 6:101.
16.
HazimC, Abubeker IbrahimR, WestercampM, et al.Establishment of a sentinel laboratory-based antimicrobial resistance surveillance network in Ethiopia. Health Secur, 2018; 16(S1):S30–S36.
17.
GandraS, Alvarez-UriaG, TurnerP, et al.Antimicrobial resistance surveillance in low- and middle-income countries: Progress and challenges in eight south Asian and southeast Asian countries. Clin Microbiol Rev, 2020; 33(3):e00048–e00019.
18.
BaiS, YuY, KuangX, et al.Molecular characteristics of antimicrobial resistance and virulence in Klebsiella pneumoniae strains isolated from goose farms in Hainan, China. Appl Environ Microbiol, 2022; 88(8):e0245721.
19.
LiS, FengX, LiM, et al.In vivo adaptive antimicrobial resistance in Klebsiella pneumoniae during antibiotic therapy. Front Microbiol, 2023; 14:1159912.
20.
BaleivanualalaSC, MatanitobuaS, SoqoV, et al.Molecular and clinical epidemiology of carbapenem resistant Acinetobacter baumannii, pseudomonas aeruginosa and enterobacterales in Fiji: A multicentre prospective observational study. Lancet Reg Health West Pac, 2024; 47:101095.
21.
ChenX, JiangZ, ChenR, et al.Nosocomial outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae ST11 in a medical intensive care unit. J Glob Antimicrob Resist, 2024; 36:436–443.
22.
VollsetSE, GorenE, YuanC-W, et al.Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: A forecasting analysis for the global burden of disease study. Lancet, 2020; 396(10258):1285–1306.
23.
TheodorakisN, FeretzakisG, HitasC, et al.Antibiotic resistance in the elderly: Mechanisms, risk factors, and solutions. Microorganisms, 2024; 12(10):1978.
24.
YaoH, YangY, YaoH, et al.Development of prediction models for carbapenem-resistant Klebsiella pneumoniae acquisition and prognosis in adult patients. Front Pharmacol, 2024; 15:1439116.
25.
KobaidzeK, JacobJ, LeongT, et al.Carbapenem-resistant Klebsiella pneumoniae: Risk factors for isolation among hospitalized patients. Brown J Hosp Med, 2023; 2(1):57568.
26.
SawaiNY, KurodaH, YamazakiY, et al.Impact assessment of an antimicrobial stewardship program in a Japanese university dental hospital. Int Dent J, 2025; 75(5):100936.
27.
GiovannenzeF, Del VecchioP, FrondiziF, et al.Effect of an educational antimicrobial stewardship programme on antibiotic prescriptions’ appropriateness in three medical units of a large university hospital: An interrupted time series analysis. J Hosp Infect, 2025; 162:127–135.
28.
OhlCA, Dodds AshleyES. Antimicrobial stewardship programs in community hospitals: The evidence base and case studies. Clin Infect Dis, 2011; 53(Suppl 1):S23–S28; quiz S29–S30.
29.
KarampatakisT, TsergouliK, IosifidisE, et al.Impact of active surveillance and infection control measures on carbapenem-resistant gram-negative bacterial colonization and infections in intensive care. J Hosp Infect, 2018; 99(4):396–404.
30.
KousouliE, ZarkotouO, PolitiL, et al.Infection control interventions affected by resource shortages: Impact on the incidence of bacteremias caused by carbapenem-resistant pathogens. Eur J Clin Microbiol Infect Dis, 2018; 37(1):43–50.
31.
MatsumuraY, YamamotoM, GomiR, et al.Integrating whole-genome sequencing into antimicrobial resistance surveillance: Methodologies, challenges, and perspectives. Clin Microbiol Rev, 2025; 38(4):e0014022.
32.
BennaniH, CornelsenL, StärkKDC, et al.Characterisation and mapping of the surveillance system for antimicrobial resistance and antimicrobial use in the United Kingdom. Vet Rec, 2021; 188(7):e10.
33.
JayatillekeK. Challenges in implementing surveillance tools of high-income countries (HICs) in low middle income countries (LMICs). Curr Treat Options Infect Dis, 2020; 12(3):191–201.
34.
MendelsonM, LaxminarayanR, LimmathurotsakulD, et al.Antimicrobial resistance and the great divide: Inequity in priorities and agendas between the global north and the global south threatens global mitigation of antimicrobial resistance. Lancet Glob Health, 2024; 12(3):e516–e521.
35.
StorrJ, KilpatrickC, LeeK. Time for a renewed focus on the role of cleaners in achieving safe health care in low- and middle-income countries. Antimicrob Resist Infect Control, 2021; 10(1):59.
36.
RobertiJ, LeslieHH, DoubovaSV, et al.Inequalities in health system coverage and quality: A cross-sectional survey of four Latin American countries. Lancet Glob Health, 2024; 12(1):e145–e155.
37.
GengY, LiuZ, MaX, et al.Infection prevention and control measures for multidrug-resistant organisms: A systematic review and network meta-analysis. Infection, 2025; 53(5):1789–1800.
